Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21540021 | 0.79 | CYP3A4 (0.38) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23869469 | 0.79 | CYP3A4 (0.38) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL27547702 | 0.79 | OPRM1 (0.32) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL7446973 | 0.76 | CYP3A4 (0.38) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20072726 | 0.74 | CYP3A4 (0.34) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12599477 | 0.73 | ALOX15 (0.44) | — | |
| SCHEMBL10644166 | 0.73 | HRH3 (0.35) | — | |
| SCHEMBL3308637 | 0.73 | SLC6A3 (0.37) | CYP3A4CYP2D6CYP2C19SLC6A2SLC6A3 | |
| SCHEMBL19272636 | 0.73 | SLC6A3 (0.37) | CYP3A4CYP2D6CYP2C19SLC6A2SLC6A3 | |
| SCHEMBL17706430 | 0.73 | OPRL1 (0.41) | CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LIMITED (IN) | 2019-09-12 | — | — | US | disclosed |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LTD (IN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | CYP3A4 784/4885CYP2D6 1127/4885CYP2C19 1878/4885 |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | CYP3A4 784/4885CYP2D6 1127/4885CYP2C19 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.